Clik here to view.
Cipher Pharma adopts 5-by-5 mantra for future growth
Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND), with newly installed CEO, Shawn O’Brien, has adopted a five-by-five strategy that sets objectives for its future growth. Shawn O’Brien “I want to...
View ArticleClik here to view.
Pivotal gets U.S. patent allowance for VASCAZEN + CAI
The U.S. Patent and Trademark Office (USPTO) has published a notice of allowance for Pivotal Therapeutics’ (OTCQX:PVTTF; CSE:PVO) patent application for claims intended to protect VASCAZEN and its...
View ArticleClik here to view.
Feltl starts Viking Therapeutics at strong buy
Feltl & Co. has launched coverage of Viking Therapeutics (NASDAQ:VKTX) with a “strong buy” rating and price target of $17.50. The stock closed at $6.90 on Wednesday. “We anticipate the company...
View ArticleClik here to view.
Delivra implementing U.S. expansion strategy for topical creams
Chris Schnarr, President & CFO The major initiative for Delivra (TSX-V:DVA) in 2016 is to introduce its flagship LivRelief topical pain and nerve creams to the U.S. market, initially through a U.S....
View Article
